All In Biotech

Drug Trial Radar · NCT05155137

Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)

Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt in Primary Health Care

Last checked: Nov 20, 2026Latest source record: Jan 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 8,518 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

8,518

Planned (sponsor's estimate)

Start

Dec 20, 2021

Primary completion

Dec 14, 2029

Study completion Dec 14, 2030

Sponsor

Lead sponsor
Hospital Moinhos de VentoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, Brazil; World Stroke Organization
First posted
Dec 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase III, prospective, placebo-controlled randomized clinical trial involving 8,518 subjects with low to moderate stroke risk, followed for 3 years in Brazil. Participants will be randomized to receive either the polypill (valsartan 80 mg, amlodipine 5 mg, and rosuvastatin 10 mg), with dose adjustment of amlodipine to 2.5 mg for patients experiencing adverse events, or a placebo, and to either use the Stroke Riskometer for lifestyle modification or receive usual care. The purpose of the study is to test whether the polypill, alone or in combination with lifestyle modification, will reduce the incidence of stroke and cognitive impairment in this population.

Conditions

  • Stroke
  • Cognitive Decline

Interventions

  • Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)Drug

    Polypill with 3 medications (Valsartan 80 mg + Amlodipine 5 mg + Rosuvastatin 10 mg)

  • Stroke RiskometerBehavioral

    Participants will be randomized to use Stroke Riskometer App for lifestyle modifications

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. StrokeTime frame: 3 years
  2. Cognitive declineTime frame: 3 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Unidade de Saúde Santa Cecília / Hospital de Clínicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital Moinhos de Vento

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.